Table 2.

Associations of selected immune cell enrichment scores with recurrence-free and overall survival among patients with triple-negative breast cancer

Model AaModel BbModel Cc
HR (95% CI)PFDRHR (95% CI)PFDRHR (95% CI)PFDR
Recurrence-free survival
CD4+ Tcm
 WCH1.45 (0.85–2.45)0.1700.6621.51 (0.82–2.79)0.1870.7981.68 (0.87–3.24)0.1220.625
 TCGA1.30 (1.01–1.66)0.0420.2501.52 (1.14–2.02)0.0040.0701.64 (1.21–2.22)0.0010.035
Meta-analysis1.33 (1.06–1.66)0.0140.2221.52 (1.17–1.97)0.0020.0351.65 (1.25–2.17)<0.0010.009
I2, PheterogeneityI2 = 0.0%, P = 0.714I2 = 75.0%, P = 0.985I2 = 75.0%, P = 0.948
Plasma cells
 WCH0.42 (0.20–0.91)0.0270.3790.43 (0.20–0.89)0.0230.4030.42 (0.20–0.90)0.0260.499
 TCGA0.47 (0.25–0.92)0.0270.2450.37 (0.18–0.75)0.0060.0700.34 (0.16–0.73)0.0060.093
Meta-analysis0.45 (0.27–0.73)0.0010.0350.40 (0.24–0.67)<0.0010.0180.38 (0.22–0.65)<0.0010.009
I2, PheterogeneityI2 = 0.0%, P = 0.825I2 = 0.0%, P = 0.775I2 = 0.0%, P = 0.698
Overall survival
Plasma cells
 WCH0.18 (0.05–0.65)0.0090.2450.19 (0.06–0.68)0.0100.3500.20 (0.05–0.75)0.0170.595
 TCGA0.49 (0.25–0.98)0.0430.2980.39 (0.18–0.81)0.0100.2100.36 (0.16–0.80)0.0120.163
Meta-analysis0.35 (0.14–0.88)0.0260.4600.32 (0.17–0.61)<0.0010.0180.31 (0.16–0.62)0.0010.035
I2, PheterogeneityI2 = 45.2%, P = 0.177I2 = 0.0%, P = 0.324I2 = 0.0%, P = 0.465
  • NOTE: Italicized text indicates that I2 statistic and Pheterogeneity were between-study heterogeneity in the meta-analysis. Bold indicates statistical significance.

  • aAdjusted for age at diagnosis, menopause status (premenopause, postmenopause, or unknown), and race (Asian, Black, White, or unknown).

  • bAdditionally adjusted for histologic type (invasive ductal/lobular carcinoma and other carcinoma), T stage (T1 and T2+), and nodal status (negative and positive).

  • cAdditionally adjusted for surgery (simple mastectomy, modified radical mastectomy, lumpectomy, or other) and radiotherapy (yes, no, or unknown).